In the first half of this year, antineoplastic drugs became popular new drugs, and the market will continue to rise in the future

[market analysis of pharmaceutical Station] in the first half of 2019, CDE undertook 3901 acceptance numbers Among the 145 new chemical drugs declared in the field of new drugs, there are more varieties of antineoplastic drugs declared, 60 varieties in total, far more than the second drug for nervous system (23 varieties) Therefore, antitumor drugs are still a hot research and development area With the continuous rise of cancer incidence rate, anti-tumor drugs have become a large market segment in pharmaceutical industry, and there are many kinds of drugs Antibody drug is one of the fourth generation tumor treatment methods after surgery, radiotherapy and chemotherapy, and it is also the focus of innovation and research "Antibody drugs have a huge market prospect and social value and are the focus of China's biological strategic layout," the industry said At present, the development of national anti-tumor drugs is very concerned, and the policy continues to give support For example, in terms of policies, while actively reducing the approval time of new drugs and imported drugs, the state has implemented zero tariffs on 28 drugs, including anti-cancer drugs, and promoted the inclusion of anti-tumor drugs in the medical insurance catalogue At the same time, in terms of supervision, anti-tumor drugs are increasingly strict in China For example, the national health and Health Commission issued the notice on the national monitoring of the clinical application of antineoplastic drugs In order to master the clinical application of antineoplastic drugs in China and further strengthen the standardized diagnosis and treatment management of tumors, the national health and Health Commission organized the National Cancer Center to develop the national monitoring network of the clinical application of antineoplastic drugs, and decided on the clinical application of antineoplastic drugs Condition monitoring With the huge market demand and favorable policies, the field of anti-tumor drugs will usher in a good opportunity for development It is predicted that in the next five years, tumor treatment drugs will still be a better field in the global market By 2022, the scale of anti-tumor drug market is expected to grow to US $192 billion, with a compound annual growth rate of 12.7% Among them, targeted drug is one of the main development directions of the anti-tumor drug industry in the future It is understood that many enterprises are actively laying out their own cancer drug pipeline On May 20, 2019, the anti-tumor generic drug gefitinib developed by Zhengda Tianqing Pharmaceutical Group obtained the drug registration approval issued by the National Drug Administration (nmpa) So that the domestic gefitinib manufacturers have formed a tripartite pattern of AstraZeneca, Qilu pharmaceutical and Zhengda Tianqing With the improvement of Chinese people's living standard step by step, great health awareness and medical needs change with each passing day In addition, under the influence of the general trend of aging population in China, many factors constitute the growing demand of drug market and promote the growth of drug market In particular, the market of antitumor drugs has attracted much attention It is understood that in the past two years, the domestic anti-tumor treatment market has accelerated the use of large molecule monoclonal antibodies and small molecule targeted drugs According to the data of the State Food and drug administration, 30 small molecule targeted drugs have been approved at present The first type of small molecule targeted drugs independently developed in China are exetinib of Beida pharmaceutical, apatinib and pyrrolidine of Hengrui pharmaceutical, fuquinotinib of Hutchison Whampoa, and androtinib of Zhengda Tianqing At the same time, the small molecule targeted generic drugs approved are imatinib and dasati Domestic small molecule targeted drugs, such as nifedipine, gefitinib, bortezomib and ledonamide, account for 1 / 3 of the total In order to provide effective drug treatment for cancer patients, China needs to continue to increase the transformation of scientific and technological achievements of anti-tumor drugs The industry said that cooperation between universities and pharmaceutical enterprises would be a better way It is understood that on May 31, Harbin Medical University signed a contract with Zhuhai tengbai Pharmaceutical Co., Ltd on the industrial transformation project, and the two sides will carry out cooperation on the industrialization of antitumor peptide drugs According to the agreement, Zhuhai tengbai Pharmaceutical Co., Ltd will pay academician Yang Baofeng 150 million yuan to purchase hyd-pep06 peptide intellectual property and clinical trial approval The drug, led by academician Yang Baofeng of Harbin Medical University, has been independently researched and developed by the team for more than 10 years In addition to inhibiting the activity of angiogenesis, it also has the effect of disintegrin, which can inhibit ion channels and micronucleotides, and realize the design of "one drug with multiple targets", so as to effectively inhibit the recurrence and metastasis of a variety of tumors Nowadays, with the increase of cancer incidence, the scale of China's anti-tumor drug market continues to grow steadily, with an average annual growth rate of 16.0% in 2012-2017 In 2018, the sales volume of anti-tumor drugs in hospitals in key cities in China reached 26.459 billion yuan, an increase of 8.88% year on year It is predicted that the sales curve of anti-tumor drug market will continue to rise in the next few years.